Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity

Journal of Immunology

Volumn 191, Issue 8, 2013, Pages 4121-4129

  Ankri, Chen ^a   Shamalov, Katerina ^a   Horovitz Fried, Miryam ^a   Mauer, Shmuel ^a   Cohen, Cyrille J ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD28 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CHICKEN; CONTROLLED STUDY; CYTOKINE RELEASE; EMBRYO; FUNCTIONAL ASSESSMENT; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD137; ANTIGENS, CD28; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; FEMALE; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885461249     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203085     Document Type: Article

References (50)

1. Appay, V., P. R. Dunbar, M. Callan, P. Klenerman, G. M. Gillespie, L. Papagno, G. S. Ogg, A. King, F. Lechner, C. A. Spina, et al. 2002. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8: 379-385.
2. Seliger, B., F. M. Marincola, S. Ferrone, and H. Abken. 2008. The complex role of B7 molecules in tumor immunology. Trends Mol. Med. 14: 550-559.
3. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12: 492-499.
4. Yokosuka, T., M. Takamatsu, W. Kobayashi-Imanishi, A. Hashimoto-Tane, M. Azuma, and T. Saito. 2012. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209: 1201-1217.
5. Latchman, Y., C. R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. Iwai, A. J. Long, J. A. Brown, R. Nunes, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2: 261-268.
6. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-Associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
7. Thompson, R. H., S. M. Kuntz, B. C. Leibovich, H. Dong, C. M. Lohse, W. S. Webster, S. Sengupta, I. Frank, A. S. Parker, H. Zincke, et al. 2006. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66: 3381-3385.
8. Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704.
9. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
10. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
11. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
12. Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116-126.
13. Bour-Jordan, H., J. H. Esensten, M. Martinez-Llordella, C. Penaranda, M. Stumpf, and J. A. Bluestone. 2011. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol. Rev. 241: 180-205.
14. Ware, C. F. 2011. The TNF receptor super family in immune regulation. Immunol. Rev. 244: 5-8.
15. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
16. Restifo, N. P., M. E. Dudley, and S. A. Rosenberg. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-281.
17. Daniel-Meshulam, I., S. Ya'akobi, C. Ankri, and C. J. Cohen. 2012. How (specific) would like your T-cells today ? Generating T-cell therapeutic function through TCR-gene transfer. Front. Immunol. 3: 186.
18. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
19. Robbins, P. F., R. A. Morgan, S. A. Feldman, J. C. Yang, R. M. Sherry, M. E. Dudley, J. R. Wunderlich, A. V. Nahvi, L. J. Helman, C. L. Mackall, et al. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29: 917-924.
20. Merhavi-Shoham, E., A. Haga-Friedman, and C. J. Cohen. 2012. Genetically modulating T-cell function to target cancer. Semin. Cancer Biol. 22: 14-22.
21. Topp, M. S., S. R. Riddell, Y. Akatsuka, M. C. Jensen, J. N. Blattman, and P. D. Greenberg. 2003. Restoration of CD28 expression in CD282 CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J. Exp. Med. 198: 947-955.
22. Zang, X., and J. P. Allison. 2007. The B7 family and cancer therapy: costimulation and coinhibition. Clin. Cancer Res. 13: 5271-5279.
23. Topalian, S. L., D. Solomon, and S. A. Rosenberg. 1989. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142: 3714-3725.
24. Houghton, A. N., F. X. Real, L. J. Davis, C. Cordon-Cardo, and L. J. Old. 1987. Phenotypic heterogeneity of melanoma: relation to the differentiation program of melanoma cells. J. Exp. Med. 165: 812-829.
25. Cohen, C. J., Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan. 2005. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 175: 5799-5808.
26. Wargo, J. A., P. F. Robbins, Y. Li, Y. Zhao, M. El-Gamil, D. Caragacianu, Z. Zheng, J. A. Hong, S. Downey, D. S. Schrump, et al. 2009. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 58: 383-394.
27. Hughes, M. S., Y. Y. Yu, M. E. Dudley, Z. Zheng, P. F. Robbins, Y. Li, J. Wunderlich, R. G. Hawley, M. Moayeri, S. A. Rosenberg, and R. A. Morgan. 2005. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16: 457-472.
28. Cohen, C. J., Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan. 2006. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66: 8878-8886.
29. Zhao, Y., Z. Zheng, C. J. Cohen, L. Gattinoni, D. C. Palmer, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2006. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13: 151-159.
30. Bialer, G., M. Horovitz-Fried, S. Ya'acobi, R. A. Morgan, and C. J. Cohen. 2010. Selected murine residues endow human TCR with enhanced tumor recognition. J. Immunol. 184: 6232-6241.
31. Haga-Friedman, A., M. Horovitz-Fried, and C. J. Cohen. 2012. Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity. J. Immunol. 188: 5538-5546.
32. Dudley, M. E., J. R. Wunderlich, T. E. Shelton, J. Even, and S. A. Rosenberg. 2003. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26: 332-342.
33. Orchard, P. J., B. R. Blazar, S. Burger, B. Levine, L. Basso, D. M. Nelson, K. Gordon, R. S. McIvor, J. E. Wagner, and J. S. Miller. 2002. Clinical-scale selection of anti-CD3/CD28-Activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Hum. Gene Ther. 13: 979-988.
34. Wilde, S., D. Sommermeyer, M. Leisegang, B. Frankenberger, B. Mosetter, W. Uckert, and D. J. Schendel. 2012. Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. J. Immunol. 189: 598-605.
35. Thomas, D. A., and J. Massagué. 2005. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369-380.
36. Gimmi, C. D., G. J. Freeman, J. G. Gribben, K. Sugita, A. S. Freedman, C. Morimoto, and L. M. Nadler. 1991. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc. Natl. Acad. Sci. USA 88: 6575-6579.
37. Kulpa, D. A., M. Lawani, A. Cooper, Y. Peretz, J. Ahlers, and R. P. Sékaly. 2013. PD-1 coinhibitory signals: the link between pathogenesis and protection. Semin. Immunol. DOI: 10.1016/j.smim.2013.02.002.
38. Daniel-Meshulam, I., M. Horovitz-Fried, and C. J. Cohen. 2013. Enhanced antitumor activity mediated by human 4-1BB-engineered T cells. Int. J. Cancer 10.1002/ijc.28320.
39. Murphy, J. B. 1913. Transplantability of tissues to the embryo of foreign species: its bearing on questions of tissue specificity and tumor immunity. J. Exp. Med. 17: 482-493.
40. Topalian, S. L., C. G. Drake, and D. M. Pardoll. 2012. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24: 207-212.
41. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
42. Iwamura, K., T. Kato, Y. Miyahara, H. Naota, J. Mineno, H. Ikeda, and H. Shiku. 2012. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Ther. 19: 959-966.
43. Borkner, L., A. Kaiser, W. van de Kasteele, R. Andreesen, A. Mackensen, J. B. Haanen, T. N. Schumacher, and C. Blank. 2010. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol. Immunother. 59: 1173-1183.
44. Prosser, M. E., C. E. Brown, A. F. Shami, S. J. Forman, and M. C. Jensen. 2012. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol. Immunol. 51: 263-272.
45. Shin, J. H., H. B. Park, Y. M. Oh, D. P. Lim, J. E. Lee, H. H. Seo, S. J. Lee, H. S. Eom, I. H. Kim, S. H. Lee, and K. Choi. 2012. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. Blood 119: 5678-5687.
46. Sadelain, M., R. Brentjens, and I. Rivière. 2009. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21: 215-223.
47. Zhong, X. S., M. Matsushita, J. Plotkin, I. Riviere, and M. Sadelain. 2010. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18: 413-420.
48. Milone, M. C., J. D. Fish, C. Carpenito, R. G. Carroll, G. K. Binder, D. Teachey, M. Samanta, M. Lakhal, B. Gloss, G. Danet-Desnoyers, et al. 2009. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17: 1453-1464.
49. Hombach, A. A., J. Heiders, M. Foppe, M. Chmielewski, and H. Abken. 2012. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. OncoImmunology 1: 458-466.
50. Song, D. G., Q. Ye, M. Poussin, G. M. Harms, M. Figini, and D. J. Powell, Jr. 2012. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119: 696-706.